- Poster #5915: Three-dimensional (3-D) Multiplex Imaging of Biomarkers in Tumor Tissue
(posted: Apr, 2017)
Clearlight presented research data at the 2017 American Association for Cancer Research (AACR) annual meeting. Includes a link to the poster with the full presentation.
- ClearLight Presents Data on the Multiplex 3D Imaging of the Tumor Microenvironment
(posted: Mar, 2017)
ClearLight announced today that it will present data at the 2017 American Association for Cancer Research meeting in Washington DC on Wednesday, April 5, 2017, 8:00 AM-12:00 PM in the Convention Center Halls A-C, poster session 43, board number 27.
- ClearLight Diagnostics Raises $3.5M in Series B Funding
(posted: Dec, 2016)
Clearlight has completed a $3.5M Series B financing round. The financing will go towards the continued technology platform and applications development using the CLARITY technology and deep imaging with COLM Light Sheet Microscopy.
ClearLight Diagnostics Raises $3.5M in Series B Funding
posted: December 6th, 2016
SUNNYVALE, Calif., December 6, 2016 (PR NEWSWIRE)
ClearLight Diagnostics, LLC, a developer of a next generation tissue processing and 3D imaging platform for research and diagnostic applications, announced today that it has completed a $3.5M Series B financing round. Existing investors, a syndicate created by Wiegers Capital Partners, LLC led the round.
The financing will go towards the continued technology platform and applications development using the CLARITY technology and deep imaging with COLM Light Sheet Microscopy. "Continuing our development efforts using the ClearLight technology platform in oncology builds on our initial Proof of Concept work to elucidate the 3-dimensional architecture of the tumor microenvironment. We are pleased with the ongoing support of our investors who have provided further validation of the potential for the ClearLight technology platform," ClearLight CEO, Sarah McCurdy said. The financing follows an initial Series A round of $2.5M for a total of $6M invested in the company.
Founded by Karl Deisseroth M.D., Ph.D., ClearLight is developing a product platform based on the CLARITY lipid-clearing technique developed by Dr. Deisseroth and colleagues at Stanford University. This technique enables the transformation of tissue into a nanoporous, hydrogel-hybridized form that is cross-linked to a three-dimensional network of hydrophilic polymers. The process produces a fully assembled, intact tissue, which is permeable to macromolecules and optically transparent, thus allowing for robust three-dimensional imaging of subcellular components (DNA, RNA and protein) and heterogeneous cellular interactions within the tumor microenvironment. This technology, paired with the development of a tissue imaging platform that includes the revolutionary microscopy method, COLM (CLARITY Optimized Light-sheet Microscopy) will enable unprecedented depth and acceleration of key biomarker 3D image analysis from lipid-cleared samples.
About ClearLight Diagnostics
ClearLight Diagnostics is a technology development company focused on the discovery, development, and commercialization of innovative technologies to significantly improve the diagnosis and treatment of a wide range of diseases with an initial focus in oncology.
View the full press release at PR Newswire
For immediate release: Clearlight Diagnostics, LLC.